HONG KONG – Looking for an immunotherapy approach against hepatitis B virus (HBV), Chinese liver disease specialist Ascletis Pharma Inc. identified a target more familiar to those working in oncology. The company licensed rights to subcutaneously administered PD-L1 antibody KN-035, developed by Suzhou Alphamab Co. Ltd., to develop for use in HBV and other viral diseases in greater China.
HONG KONG – South Korean pharmaceutical companies Bridge Biotherapeutics Inc. and Daewoong Pharmaceutical Co. Ltd. have forged a partnership to develop a drug candidate targeting pellino proteins for treating ulcerative colitis (UC).
HONG KONG – Clinical-stage biotech firm Athenex Inc. out-licensed to Chongqing Jingdong Junzhuo Pharmaceutical Co. Ltd. the rights to commercialize an ointment known as KX2-391 for treating actinic keratosis and oncology indications in China. Under the terms, Athenex will receive an up-front payment of $14.5 million and up to $15 million for development milestones. The company is also entitled to tiered royalties based on annual net sales starting at 15 percent, and with incremental increases of royalties with growing sales.
HONG KONG – South Korean pharmaceutical companies Bridge Biotherapeutics Inc. and Daewoong Pharmaceutical Co. Ltd. have forged a partnership to develop a drug candidate targeting pellino proteins for treating ulcerative colitis (UC).
HONG KONG – Clinical-stage biotech firm Athenex Inc. out-licensed to Chongqing Jingdong Junzhuo Pharmaceutical Co. Ltd. the rights to commercialize an ointment known as KX2-391 for treating actinic keratosis and oncology indications in China. Under the terms, Athenex will receive an up-front payment of $14.5 million and up to $15 million for development milestones. The company is also entitled to tiered royalties based on annual net sales starting at 15 percent, and with incremental increases of royalties with growing sales.
HONG KONG – Chinese clinical-stage biotech Connect Biopharmaceuticals Ltd., of Suzhou, secured $55 million in a series B financing to move forward its two lead drug candidates, CBP-307 for treating ulcerative colitis and Crohn's disease and CBP-201 for treating atopic dermatitis, to the next stage.
HONG KONG - Chinese clinical-stage biotech Antengene Corp. raised $120 million in series B financing to move forward its lead programs, ATG-008 and ATG-010 (selinexor), for treating blood cancer and liver cancer, respectively.
HONG KONG – South Korean pharmaceutical company Yuhan Corp. is banking $15 million up front in a potential $785 million deal with U.S. biotech Gilead Sciences Inc. to develop novel therapeutic candidates that treat patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
HONG KONG – South Korean pharmaceutical company Yuhan Corp. is banking $15 million up front in a potential $785 million deal with U.S. biotech Gilead Sciences Inc. to develop novel therapeutic candidates that treat patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
